Capricor Therapeutics, Inc. Common Stock CAPR
i
Market datapartial · fetched 2026-11-10T22:18:54.068Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T22:18:31.263732646Z
FundamentalsAlpha Vantage · unavailable
Capricor Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 8.25 | 516.7% | 24.3% | |||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 10.35 | 634.7% | 19.1% | |||
| 50Δ | 11.28 | 663.7% | 17.2% | |||
| 55Δ | 12.43 | 693.9% | 15.2% | |||
| 60Δ | 14.70 | 800.0% | 14.9% | |||
| 65Δ | 8.79 | 400.2% | 10.6% | 15.28 | 744.4% | 12.0% |
| 70Δ | 16.75 | 742.6% | 9.4% | |||
| 75Δ | ||||||
| 80Δ | 7.13 | 506.5% | 6.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.25
- IV
- 516.7%
- B/E move
- 24.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.35
- IV
- 634.7%
- B/E move
- 19.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.28
- IV
- 663.7%
- B/E move
- 17.2%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.43
- IV
- 693.9%
- B/E move
- 15.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.70
- IV
- 800.0%
- B/E move
- 14.9%
65Δ
- Pseudo strike
- 8.79
- IV
- 400.2%
- B/E move
- 10.6%
- Pseudo strike
- 15.28
- IV
- 744.4%
- B/E move
- 12.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.75
- IV
- 742.6%
- B/E move
- 9.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 7.13
- IV
- 506.5%
- B/E move
- 6.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 329.51% | |
| 359.13% | |
| 296.09% | |
| 356.98% | |
| 324.03% | |
| 488.49% | |
| 480.97% | |
| 361.01% | |
| 369.54% | |
| 343.23% |
Biotechnology
CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement…
More →CCCC
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer,…
More →CDXS
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
More →CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Description unavailable
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →